Clinical Trial Update: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effects of canagliflozin on renal and cardiovascular outcomes in patients with type 2 diabetes and diabetic nephropathy; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Diabetes Mellitus, Type 2, Diabetic Nephropathy | Phase 3 | Status: COMPLETED | Results posted: 2019-11-20